Worth reading
47Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
2.4
Hundreds of millions of yenWording
Conditional
How definitive the wording is.Agreements reached under this partnership
Business alliance4263SUSMED,Inc.
Alliance partnerKYORIN Pharmaceutical Co.,Ltd.
Details of the alliance
- 1
Joint research and development and sales of therapeutic apps in the otolaryngology field
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
About the partner
LocationChiyoda-ku, Tokyo
Impact on Business Performance
The amount is expected to be recorded as business revenue in the fourth quarter of the fiscal year ending June 2026.
Contract Date9 November 2022
| Item | Details |
|---|---|
| Name of alliance partner | KYORIN Pharmaceutical Co.,Ltd. |
| Alliance partner's location | Chiyoda-ku, Tokyo |
| Type of alliance | Business alliance |
| Details of the alliance | Joint research and development and sales of therapeutic apps in the otolaryngology field |
| Contract Date | 9 November 2022 |
| Impact on Business Performance | The amount is expected to be recorded as business revenue in the fourth quarter of the fiscal year ending June 2026. |
Items this document does not state (17)
Alliance partner's business activitiesAlliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionAlliance start dateShare Acquisition Date and Payment DateChange in major shareholders
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Use of the tinnitus treatment app developed by the two companies began in a confirmatory study.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.